ASPET 2023 Annual Meeting Abstract - Pharmacogenomics and Translational Pharmacology 2023
DOI: 10.1124/jpet.122.216680
|View full text |Cite
|
Sign up to set email alerts
|

Renoprotective Effects of Empagliflozin Against Experimentally Induced Renal Fibrosis In Vitro

Abstract: ID 21668 Poster Board 454 Background: Chronic kidney disease (CKD) is a progressive disease characterized by gradual loss of kidney function over time. Diabetes, hypertension, and obesity are the leading risk factors for developing CKD. Fibrosis is regarded as the final common pathway leading to CKD due to the irreversible damage it causes to the nephrons. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors (Dapagliflozin and Canagliflozin) have been shown to be renoprotective in type 2 diabetes patients. … Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles